AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02172040
Drug: Over-encapsulated 200 mg celecoxib capsule
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Trial: NCT03204045
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mL mixture of fentanyl with isotonic saline
Trial: NCT01916447
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Trial: NCT00426218
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01461967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses
Trial: NCT01461967
Drug: RO5508887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses
Trial: NCT01461967
Drug: RO5508887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses
Trial: NCT00761332
Drug: antiresorptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment will be prescribed according to usual standard of care
Trial: NCT01077284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching capsules
Trial: NCT02023099
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Trial: NCT02023099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04117711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered once in the morning before breakfast
Trial: NCT00472199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03296488
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
Trial: NCT01901302
Drug: CB-5945
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02233504
Drug: Exjade® (deferasirox, ICL670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03349281
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via IV each cycle on day 2.
Trial: NCT03349281
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
Trial: NCT03349281
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
Trial: NCT00324571
Drug: Calcium-based phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222532
Drug: Tetronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
Trial: NCT02222532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
Trial: NCT00082576
Drug: Azithromycin/Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396721
Drug: ACE inhibitor + statin
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
Trial: NCT00006747
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01783821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
Trial: NCT01536795
Drug: WR 279,396 with Gauze and Tape Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
Trial: NCT00650416
Drug: Coreg® Tablets 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5mg, single dose fasting
Trial: NCT00094549
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02696954
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
Trial: NCT03792841
Drug: Cytochrome P450 (CYP) Cocktail
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Trial: NCT03204318
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Trial: NCT03204318
Drug: Estradiol/norethindrone acetate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Trial: NCT02066389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT00004171
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03873038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
Trial: NCT02467673
Drug: Micronized estradiol + progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
Trial: NCT02467673
Drug: Nanoparticulate estradiol + progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
Trial: NCT02095405
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring.
Trial: NCT02055274
Drug: LY03003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00807053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03479502
Drug: Methylprednisolone Injectable Product
RxNorm normalized name: methylprednisolone Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
Trial: NCT03479502
Drug: Doxycycline Injection
RxNorm normalized name: doxycycline Injection
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 intra-articular injections of Doxycycline Injection spaced every two weeks
Trial: NCT03191526
Drug: KW-0761 0.3 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection every 12 weeks.
Trial: NCT03191526
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection every 12 weeks.
Trial: NCT00676663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching entinostat tablet orally once per week
Trial: NCT00354809
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325mg, one tablet orally every day, 6 months
Trial: NCT02223299
Drug: deplin
RxNorm normalized name: Deplin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg daily for 30 days
Trial: NCT01524068
Drug: Standard Steroid Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
Trial: NCT04415151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be administered.
Trial: NCT00098202
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02800941
Drug: Oral anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment is delivered according to the usual practice.
Trial: NCT03050541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01752634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PFS for s.c. administration.
Trial: NCT02922894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill before-bedtime
Trial: NCT03071679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03196375
Drug: Placebo ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ODT taken three times daily for 28 days
Trial: NCT00919542
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 40mg daily then reducing regimen over 16 weeks
Trial: NCT01451164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered once daily
Trial: NCT01973335
Drug: High-dose loop diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
Trial: NCT01973335
Drug: Upfront therapy with oral spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not.
Trial: NCT01326000
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard iv chemotherapy
Trial: NCT01326000
Drug: RO5083945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
Trial: NCT01458951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral BID
Trial: NCT00924833
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet BID
Trial: NCT03249272
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
Trial: NCT01153997
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Trial: NCT03182634
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182634
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01164917
Drug: AMG811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
Trial: NCT03453112
Drug: Foster 100/6mg NEXThaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
Trial: NCT02826577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose
Trial: NCT02325245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
Trial: NCT04081831
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follow clinical administration
Trial: NCT01153997
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Trial: NCT02408978
Drug: OXP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02408978
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01636947
Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Trial: NCT02488590
Drug: ICS
RxNorm normalized name: ICSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Trial: NCT02488590
Drug: LABA + ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Trial: NCT02488590
Drug: other
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Trial: NCT00322764
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04283474
Drug: XG005-03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
Trial: NCT04283474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical formulation
Trial: NCT01840800
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607280
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
Trial: NCT01534806
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac(0.5mg/kg) IV push
Trial: NCT01534806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% - 10 mL IV push
Trial: NCT00253552
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02503644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical capsules without active substance
Trial: NCT02368210
Drug: 122-0551 Foam
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Foam
Trial: NCT00253552
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00732498
Drug: In-Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
Trial: NCT00732498
Drug: Y-Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
Trial: NCT03394508
Drug: ALK diluent 0,3% human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
Trial: NCT01107171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tang-min-Ling pills analogue 6g,tid,po
Trial: NCT00942188
Drug: LY2189102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
Trial: NCT00942188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2 SC injections weekly for 12 weeks.
Trial: NCT03745105
Drug: Piroxicam Injectable Solution
RxNorm normalized name: piroxicam Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
Trial: NCT00507065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01851980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT03603275
Drug: New FVIII products
RxNorm normalized name: New Day Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kovaltry or Jivi prescribed by the treating Physician
Trial: NCT01558245
Drug: tissue kallikrein
RxNorm normalized name: Tissue kallikrein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
Trial: NCT02465606
Drug: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
Trial: NCT00941824
Drug: mycophénolate acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily
Trial: NCT00513292
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00366652
Drug: desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no